• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Alternative treatment for acute promyelocytic leukemia promising

bys25qthea
July 11, 2013
in Chronic Disease, Oncology
Reading Time: 3 mins read
Alternative treatment for acute promyelocytic leukemia promising
Share on FacebookShare on TwitterShare on LinkedIn

Image: PD

1. Patients with newly-diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) plus arsenic trioxide experienced similar outcomes to patients treated with conventional ATRA plus anthracycline-based chemotherapy. 

2. Patients with APL treated with ATRA plus arsenic trioxide experienced significantly lower rates of hematologic side effects (neutropenia, thrombocytopenia, fever of unknown origin, infectious episodes) but significantly higher rates of hepatic toxic effects and prolongation of the QTc interval. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: This randomized control study showed that in newly diagnosed patients with low-to-intermediate risk APL, combination induction and consolidation therapy with ATRA and arsenic trioxide was non-inferior to the current standard-of-care treatment with ATRA-anthracycline chemotherapy. Benefits of combination therapy with arsenic trioxide were measured in terms of event-free survival at 2 years after diagnosis and appear to derive from reduced incidence of severe cytopenias, mucositis, and infections, which were more commonly associated with chemotherapy.  However, these benefits were counterbalanced by a significantly increased rate of toxic hepatic effects and prolonged QTc intervals in patients treated with ATRA-arsenic trioxide, warranting close monitoring of serum electrolytes, liver transaminases, and cardiac arrhythmias. The median follow-up period of 34.4 months suggests that future studies, potentially with larger treatment groups, will be required to investigate the longer term usage of this drug combination.

Click to read the study, published today in NEJM

RELATED REPORTS

Obesity associated with higher early-onset cancer risk among young Korean adults

Sexual minority health care providers report more depression, psychological distress, and cost-related barriers to care

Relevant Reading: Management of acute promyelocytic leukemia

In-Depth [randomized control trial]: This study compared the efficacy and adverse effect profiles of ATRA-arsenic trioxide versus standard-of-care ATRA-chemotherapy for the treatment of newly diagnosed APL classified as low-to-intermediate risk (WBC count at diagnosis ≤ 10×109 per liter).  162 patients were randomized into either treatment arm from multiple centers across three countries.

The primary end point was event-free survival at 2 years after diagnosis, with treatment failure defined as lack of complete hematologic or molecular remission after induction therapy or three consolidation courses respectively, molecular relapse, hematologic collapse, or death. The median follow-up period was 34.4 months.

97% of patients in the ATRA-arsenic trioxide group were alive and event-free at 2 years as compared with 86% in the ATRA-chemotherapy group (95% CI 2 to 22 percentage points, P<0.001 for noninferiority and P=0.02 for superiority).  Severe neutropenia and severe thrombocytopenia lasting more than 15 days were significantly more frequent in the ATRA-chemotherapy group than the ATRA-arsenic trioxide group. There were 59 episodes of fever of unknown origin and infections in the ATRA-chemotherapy group versus 26 episodes in the ATRA-chemotherapy group (P<0.001). However, 63% of patients in the ATRA-arsenic trioxide group versus 6% in the ATRA-chemotherapy group experienced severe hepatic toxicity (P<0.001).

By Matthew Growdon and Mitalee Patil

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

 

Tags: acute promyelocytic leukemiacancerhealthleukemia
Previous Post

Pneumococcal vaccine associated with a decrease in pneumonia hospitalizations

Next Post

The PIVOT trial: Radical prostatectomy versus observation [Classics Series]

RelatedReports

Obesity measurement collage: a bathroom scale with a blank dial, a loose cloth measuring tape, an apple and a pear
Chronic Disease

Obesity associated with higher early-onset cancer risk among young Korean adults

November 13, 2026
Depression collage: a calm young man in a sweater looking toward a window where light breaks through a cloud
All Specialties

Sexual minority health care providers report more depression, psychological distress, and cost-related barriers to care

November 10, 2026
Clinical AI collage: a thoughtful clinician in a white coat beside a network of blue dots, a closed blank folder and a ribbon
All Specialties

AI-drafted responses to patient messages linked to faster reply times but no drop in after-hours work for clinicians

November 3, 2026
A stylized illustration featuring the pancreas and kidney, with visual elements suggesting pain and chemotherapy effects, related to pancreatic cancer treatment.
Artificial Intelligence

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

October 30, 2026
Next Post

The PIVOT trial: Radical prostatectomy versus observation [Classics Series]

African Americans, obese overrepresented in young heart failure cases

Everolimus only protects against early cardiac allograft vasculopathy

Antibiotic implants reduce surgical site infections

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
  • Pelacarsen lowers lipoprotein(a) but does not reduce major cardiovascular events in patients with established cardiovascular disease
  • Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.